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ormoIntroduction
Anti-Müllerian hormone (AMH) is becoming commonly used in
a range of clinical situations in reproductive medicine clinics. Much
of the work on AMH is concentrated on its role as an ovarian reserve
marker. The emerging value of AMH in the diagnosis and follow-up
of patients with granulosa cell tumor (GCT) of the ovary and its vital
role in predicting fertility preservation strategies in female patients
needing chemotherapy for malignancies has expanded the use of
AMH in clinical practice.
Case Report
We report a case of a 29-year-old woman who was seen in the repro-
ductive medicine clinic with a 2-year history of secondary subfertility.
She gave a history of 2 previous spontaneous conceptions: 1 resulting in
a live birth and the other resulting in a first-trimester miscarriage. She did
not give a history of significant past medical or family illness and had
normal results on cervical smears.
She underwent basic investigations for subfertility, including de-
termination of follicle-stimulating hormone (FSH) levels on day 2 of
her cycle, AMH levels, progesterone levels on day 21 of her cycle,
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Clinical Pra
● Anti-Müllerian hormone (AMH), also known as Mülle-
rian inhibiting substance (MIS) is produced by the
granulosa cells of the ovary.
● The past decade has seen very useful advances in the
role of AMH as an ovarian reserve marker in in vitro
fertilization (IVF) treatment.
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sessment, and a semen analysis of her partner.
The results of her hormonal blood tests showed FSH levels of
0.3 IU/L, luteinizing hormone levels of 4.3 IU/L, and estradiol
levels of 369 pmol/L. AMH levels were elevated at 99.54 pmol/L
(second-generation assay). HyCoSy confirmed tubal patency but
showed a suspicious area on the left ovary with increased vascu-
larity demonstrated within the ovary. Magnetic resonance imag-
ice Points
● Through this case report we share our experience of
the use of AMH in the diagnosis and management of
an asymptomatic woman with a granulosa cell tumor
(GCT).
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bing (MRI) of the pelvis suggested a solid tumor arising from the
left ovary (Figure 1). Tumor markers that included serum alpha-
fetoprotein, cancer antigen 125, and human chorionic gonado-
tropin were normal. This patient was asymptomatic.
Given the unusually high AMH levels and low FSH levels, along with
the MRI findings for the left ovary, this case was discussed by a multi-
disciplinary team consisting of specialists from the reproductive medi-
cine team, oncologists, and pathologists. The woman underwent a lap-
arotomy for a suspected ovarian tumor.
At laparotomy, a 10-cm complex left ovarian mass was identified,
which appeared to be confined to the ovary macroscopically. The
uterus, fallopian tubes, and the other ovary were normal. The patient
underwent a left salpingo-oophorectomy along with an omental bi-
opsy. Histologic examination confirmed the presence of a GCT with
the presence of a fibrothecoma in the stroma and Sertoli cells con-
tained within the ovarian capsule (Figure 2). There was no metastasis
seen in the omental biopsy specimen.
Chemotherapy was not required and the patient made a good
recovery. Follow-up blood results 1 month after surgery showed a fall
Figure 2 Histology Views of the Tumor
3. Positive staining with calretinin on glandular structures 
1.Tumor cells in cords and glandular structures with intervening
stroma of bland spindle cells. H & E stainingin the AMH levels (39.09 pmol/L).This woman was keen to complete her family and underwent in
vitro fertilization (IVF) treatment 6 months after her surgery. She
conceived after successful treatment.
Discussion
AMH, a glycoprotein also known as Müllerian inhibiting sub-
stance (MIS), is produced by the granulosa cells of the ovary and
Sertoli cells of the testis. AMH belongs to the transforming growth
factor- family and is structurally related to the hormone inhibin.
In female individuals, AMH is either undetectable or just detect-
ble in the cord blood at birth and shows minimal increase through-
ut the prepubertal years. It is therefore undetectable in most prepu-
ertal girls.1
GCT of the ovary constitutes 3% of all ovarian tumors. These are
sex cord stromal neoplasms derived from stem cells in the ovarian
cortex. These tumors are often localized within the ovary. The ma-
jority of patients present with stage 1 tumors with a 90% 5-year
survival rate. Dissemination of these tumors is generally intraperito-
neal, and only in the late stages of the disease does systemic metastasis
4. Alpha GST staining of small glandular structures 
2. Prominent nuclear grooves in granulose cells. H & E staining occur.
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AMH in Diagnosing Granulosa Cell Tumor
96 CThe diagnostic role of AMH in the detection of GCT was first
reported by Gustafson et al in 1992 in a patient with GCT.2 Rey et
l in 1996 studied 16 patients with GCT and concluded that serum
MH levels were a more reliable test than estradiol or inhibin levels
n the diagnosis and follow-up of these tumors.3 A study by Lane et
l in 1999 evaluated the role of serial AMH testing in 17 patients.4
Serum AMH levels were elevated in 6 of 8 patients with juvenile
GCT and in 7 of 9 patients with adult GCT. More recently in 2011,
a study reported by Almeida et al measured AMH levels in 23 mares.5
Their study showed that AMH levels were high in mares with GCT
and decreased after oophorectomy. AMH receptors were also de-
tected by immunohistochemical methods in the tumor and ovarian
cyst fluid.
The diagnostic accuracy of AMH determinations was reported in
2007 by Marca and Volpe.6 The test had a sensitivity ranging be-
tween 76% and 93% and a specificity of 96% using new second-
generation assays for measuring the AMH levels. This appeared to be
superior to the previously used tests such as determining estradiol
and inhibin levels. Estradiol levels seem to be elevated in patients
with GCT. Unfortunately because of the lack of sensitivity, this test
is currently of limited value. Inhibin is a glycoprotein that has 2
subunits, A and B. Both these subunits are known to be elevated in
women with GCT. However the test is not as reliable and requires a
5-day assay, which is less practical.
In the previous studies, AMH levels were studied in patients di-
agnosed with GCT. In our patient, raised AMH levels along with
imaging studies aided the diagnosis of GCT in an asymptomatic
woman.
The past decade has seen very useful advances in the role of AMH
in a range of clinical situations. Although there is a vast collection of
articles on the value of AMH in predicting response of the ovaries in
an IVF cycle, there are comparatively fewer case reports in the liter-
linical Ovarian & Other Gynecologic Cancer December 2012ature that have mentioned the role of AMH in the diagnosis and
follow-up of GCT.
Conclusion
Our case report highlights the role of AMH in the diagnosis of
GCT in an asymptomatic patient. It thereby adds to the existing
knowledge of AMH in this rapidly advancing field of medicine.
Appendix
Anti-Müllerian hormone (AMH) second-generation assay refer-
ence range:7
Optimal fertility, 40.04 to 67.09 pmol/L
Satisfactory fertility, 21.98 to 40.03 pmol/L
Low fertility, 3.08 to 21.97 pmol/L
Very low/undetectable fertility, 0.0 to 3.07 pmol/L
High levels 67.09 pmol/L are suggestive of polycystic ovar-
ian disease or granulosa cell tumors
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